



Dkt. 43016-C/JPW/AKC/JKM #15

Philip O. Livingston and Friedhelm Hellings
 U.S. Serial No.: 08/475,784 Group Unit: 1806
 Filed: June 7, 1995 Examiner: A. Caputa
 For: GANGLIOSIDE-KLH CONJUGATE VACCINES WITH QS-21

1185 Avenue of the Americas
 New York, New York 10036
 May 2, 1997

RECEIVED

Assistant Commissioner for Patents
 Washington, D.C. 20231

MAY 22 1997

Sir:

GRN 12 1997

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. §1.56(c) and §1.97(c), applicants would like to direct the Examiner's attention to the following disclosure which is listed on the attached Form PTO-1449 (Exhibit 1) and attached hereto as Exhibits 2-6:

1. Hellings, F., et al. (March 1993) "Increased immunogenicity of GM2 conjugated with KLH and used with adjuvants in patients with melanoma." Proceedings Of The 84th Annual Meeting Of The American 34: 491 (Exhibit 2);
2. Hellings, F., et al. (August 1993) "Construction of immunogenic GD-3 conjugate vaccines." Annals Of The New York Academy Of Sciences 690: 396-397 (Exhibit 3);
3. Hellings, F., et al. (1994) "GD3 vaccines for melanoma superior immunogenicity of keyhole limpet hemocyanin conjugate." Cancer Research 54: 197-203 (Exhibit 4);
4. Bystryn, J-C (1990) "Tumor vaccines." Cancer And Metastasis Reviews 9: 81-91 (Exhibit 5); and

Philip O. Livingston and Friedhelm Helling
U.S. Serial No. 08/475,784
Filed: June 7, 1995
Page 2

5. Ritter, G., et al. (1990) "Induction of antibodies reactive with GM2 ganglioside after immunization with lipopolysaccharides for *Campylobacteria jejuni*." Int. J. Cancer 66: 184-190 (Exhibit 6).

The references, enclosed as Exhibits 2-5, were cited in the Supplementary European Search Report issued in connection with European Application No. 94 90 7279.7, filed August 22, 1995, corresponding to PCT International Application No. PCT/US94/00757, filed January 21, 1994. The subject application is a continuation application of PCT/US94/00757. A copy of the Supplementary European Search Report is attached hereto as Exhibit 7.

Further, the reference, enclosed as Exhibit 6, was cited by the New Zealand Patent Office during the substantive examination of New Zealand Application No. 261744, filed July 28, 1995, corresponding to PCT International Application No. PCT/US94/00757, filed January 21, 1994. The subject application is a continuation application of PCT/US94/00757.

Applicants maintain that the subject invention is novel and nonobvious over the teachings disclosed in the above-identified publications. Accordingly, applicants maintain that the above-identified publications neither disclose nor suggest the invention claimed in the subject application.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee, other than the \$230.00 fee under 37 C.F.R. §1.17(p), is deemed necessary in connection with the filing of this Supplemental Information Disclosure Statement. However, if any

Philip O. Livingston and Friedhelm Helling
U.S. Serial No. 08/475,784
Filed: June 7, 1995
Page 3

other fee is required, authorization is hereby given to charge
the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,

Albert Wai-Kit Chan

I hereby certify that this correspondence
is being deposited this date with the U.S.
Postal Service with sufficient postage as
first class mail in an envelope addressed
to: Assistant Commissioner for Patents,
Washington, D.C. 20231.

Albert Wai-Kit Chan
Albert Wai-Kit Chan
Reg. No. 36,479

5/2/97
Date

John P. White
Registration No. 28,678
Albert Wai-Kit Chan
Registration No. 36,479
Attorneys for Applicant(s)
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

Form PTO-1449 INFORMATION DISCLOSURE CITATION MAIN IN AN APPLICATION <i>36 (Use only if necessary)</i>			Docto Number (Continued) 43016-C/JPW/AKC/JKM	Application Number 08/475,784
			Applicant Philip O. Livingston and Friedhelm Helling	
			Filing Date June 7, 1995	Group Art Unit 1806
U. S. PATENT DOCUMENTS				
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS SUB CLASS
RECEIVED JUN 22 1995 CGRN 10 1995				
FOREIGN PATENT DOCUMENTS				
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS SUBCLASS
TRANSLATION YES NO				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
	Helling, F., et al. "Increased immunogenicity of GM2 conjugated with KLH and used with adjuvants in patients with melanoma." March 1993			
	Proceedings Of The 84th Annual Meeting Of The American Association For Cancer Research 34: 491			
	Helling, F., et al. "Construction of immunogenic GD-3 conjugate vaccines." August 1993 Annals Of The New York Academy Of Sciences			
	EXAMINER		DATE CONSIDERED	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.				

